Damasceno Marina B M V, de Melo Júnior José de Maria A, Santos Sacha Aubrey A R, Melo Luana T M, Leite Laura Hévila I, Vieira-Neto Antonio E, Moreira Renato de A, Monteiro-Moreira Ana Cristina de O, Campos Adriana R
Experimental Biology Centre (NUBEX), University of Fortaleza (UNIFOR), Fortaleza, Ceará, Brazil.
Department of Physical Therapy, University of Toronto (UofT), Toronto, Ontario, Canada.
Chem Biol Interact. 2016 Aug 25;256:9-15. doi: 10.1016/j.cbi.2016.06.016. Epub 2016 Jun 11.
Orofacial pain is a highly prevalent clinical condition, yet difficult to control effectively with available drugs. Much attention is currently focused on the anti-inflammatory and antinociceptive properties of lectins. The purpose of this study was to evaluate the antinociceptive effect of frutalin (FTL) using rodent models of inflammatory and neuropathic orofacial pain. Acute pain was induced by formalin, glutamate or capsaicin (orofacial model) and hypertonic saline (corneal model). In one experiment, animals were pretreated with l-NAME and naloxone to investigate the mechanism of antinociception. The involvement of the lectin domain in the antinociceptive effect of FTL was verified by allowing the lectin to bind to its specific ligand. In another experiment, animals pretreated with FTL or saline were submitted to the temporomandibular joint formalin test. In yet another, animals were submitted to infraorbital nerve transection to induce chronic pain, followed by induction of thermal hypersensitivity using acetone. Motor activity was evaluated with the rotarod test. A molecular docking was performed using the TRPV1 channel. Pretreatment with FTL significantly reduced nociceptive behaviour associated with acute and neuropathic pain, especially at 0.5 mg/kg. Antinociception was effectively inhibited by l-NAME and d-galactose. In line with in vivo experiments, docking studies indicated that FTL may interact with TRPV1. Our results confirm the potential pharmacological relevance of FTL as an inhibitor of orofacial nociception in acute and chronic pain mediated by TRPA1, TRPV1 and TRPM8 receptor.
口面部疼痛是一种非常普遍的临床病症,但现有药物难以有效控制。目前,许多注意力集中在凝集素的抗炎和抗伤害感受特性上。本研究的目的是使用炎症性和神经性口面部疼痛的啮齿动物模型评估弗鲁他林(FTL)的抗伤害感受作用。通过福尔马林、谷氨酸或辣椒素(口面部模型)和高渗盐水(角膜模型)诱导急性疼痛。在一项实验中,动物用L-硝基精氨酸甲酯(l-NAME)和纳洛酮预处理以研究抗伤害感受的机制。通过使凝集素与其特异性配体结合来验证凝集素结构域在FTL抗伤害感受作用中的参与。在另一项实验中,用FTL或生理盐水预处理的动物接受颞下颌关节福尔马林试验。在又一项实验中,动物接受眶下神经横断以诱导慢性疼痛,随后用丙酮诱导热超敏反应。用转棒试验评估运动活性。使用瞬时受体电位香草酸亚型1(TRPV1)通道进行分子对接。用FTL预处理可显著降低与急性和神经性疼痛相关的伤害性行为,尤其是在0.5mg/kg时。l-NAME和D-半乳糖可有效抑制抗伤害感受作用。与体内实验一致,对接研究表明FTL可能与TRPV1相互作用。我们的结果证实了FTL作为TRPA1、TRPV1和TRPM8受体介导的急性和慢性疼痛中口面部伤害感受抑制剂的潜在药理学相关性。